Description

Noopept Tablets

Noopept
CAS Number	157115-85-0
Molar Mass	318.373 g·mol−1
Chemical Formula	C17H22N2O4
IUPAC Name	Ethyl 1-(phenylacetyl)-l-prolylglycinate.

Introduction

Noopept Tablets is a meticulously formulated research product explicitly designed for scientific exploration, with a clear distinction from any association with human consumption. This tablet form of Noopept serves as a valuable tool for researchers investigating its unique properties and potential benefits in various research domains.

Key Characteristics

Noopept is a nootropic compound known for its cognitive-enhancing effects. It is recognized for its potential neuroprotective properties and has become a focus of research in the field of neuroscience.

Research Applications

Noopept Tablets finds versatile applications in research domains, providing researchers with a tool to explore its potential benefits. Its applications extend to investigations into cognitive disorders, neuroprotection, and potential implications for diabetes.

Research Benefits

Cognitive Disorder

Studies suggest that Noopept may have potential applications in addressing cognitive disorders. Research in this domain aims to understand its mechanisms of action and potential therapeutic applications in conditions related to cognitive impairment.

Neuroprotection

Preliminary research indicates that Noopept may have neuroprotective properties, potentially influencing neuronal survival and function. Investigations into its effects on protecting the brain from damage contribute to understanding its potential applications in neuroprotection.

Diabetes

Research suggests that Noopept may have implications for diabetes, potentially influencing glucose metabolism. Studies exploring its effects on diabetes-related parameters contribute to understanding its potential applications in metabolic health.

Summary

Noopept Liquid, developed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in cognitive disorders, neuroprotection, and potential implications for diabetes. The distinctive characteristics of Noopept make it a promising subject for further exploration in neuroscientific and metabolic research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009 Mar;39(3):311-21. doi: 10.1007/s11055-009-9128-4. PMID: 19234797. [Read More].
2. Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. 2014 Aug 6;21(1):74. doi: 10.1186/s12929-014-0074-2. PMID: 25096780; PMCID: PMC4422191. [Read More].
3. Perihan Gürbüz, Halil Düzova, Azibe Yildiz, Pınar Çakan, Gül Büşra Kaya, Harika Gözde Gözükara Bağ, Merve Durhan, Cemile Ceren Gül, Aslı Çetin Taşlidere,
   Effects of noopept on cognitive functions and pubertal process in rats with diabetes, Life Sciences, Volume 233, 2019, 116698, ISSN 0024-3205, https://doi.org/10.1016/j.lfs.2019.116698. [Read More].